34 / 48
Solomon B JCO 2018
Survival probability at 4 yrs =
56.6% (95% CI 48.3, 64.1) for
crizotinib, median OS NR
(45.8,NR)
Median OS was longest (NR) in
57 patients who received
crizotinib then another ALK TKI
Median OS was 20.8 months in
37 patients who received
crizotinib then treatment other
than an ALK TKI
PROFILE 1014: Final Overall Survival Analysis
Among p. randomly assigned to
Crizotinib,
73%
with PD continued to
receive
Crizotinib beyond disease
progression
for a median of
3.1 ms
(range, 0.7 to 22.6)
J Clin Oncol 36:2251-2258. © 2018